AI Summary Trikafta (elexacaftor/tezacaftor/ivacaftor) is a combination CFTR modulator for cystic fibrosis with eligible CFTR mutations and is not specifically approved to treat liver disease.
Medically reviewed.
Trikafta (elexacaftor/tezacaftor/ivacaftor) is a prescription combination CFTR modulator. It treats cystic fibrosis (CF) in people with eligible CFTR gene mutations by improving how the defective CFTR protein works. In people with cystic fibrosis-associated liver disease (CFLD), improving the underlying CFTR defect may also support liver health. Trikafta is not specifically approved to treat liver disease. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Trikafta's role in CF care: how it works, who may be prescribed it, how it is used, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT TRIKAFTA TREATMENT
Trikafta is a prescription medicine that combines three drugs: elexacaftor, tezacaftor, and ivacaftor. Together they act as a CFTR modulator. It treats cystic fibrosis (CF) in people with eligible CFTR gene mutations.
By improving the function of the defective CFTR protein, Trikafta helps improve chloride transport, lung function, and overall health.
People with CF can develop cystic fibrosis-associated liver disease (CFLD). In these patients, improving the underlying CFTR defect may also help support liver health. Trikafta is not specifically approved to treat liver disease.
It is one part of routine CF care, along with regular monitoring by your healthcare provider, such as Liver Function Tests (LFTs).
WHO TRIKAFTA MAY BE SUITABLE FOR
Your healthcare provider may prescribe Trikafta if you have cystic fibrosis with an eligible CFTR mutation. Genetic testing confirms whether you are eligible for CFTR modulator therapy.
It may also be considered if you need treatment to improve CFTR protein function, or if you have pulmonary (lung) manifestations of cystic fibrosis.
Your medical history, current health status, liver condition, and other medications all factor into the decision. Treatment decisions are individualized and should be made by a qualified healthcare professional.
ELIGIBILITY OVERVIEW
Trikafta may be considered when the following apply:
Before recommending Trikafta, healthcare providers review several factors, including:
HOW TRIKAFTA CAN HELP
Cystic fibrosis is caused by a defective CFTR protein. Trikafta improves how this protein is processed and moved to the cell surface. It increases the amount of working CFTR protein at the cell surface.
This enhances the movement of chloride and water across epithelial cells, which improves mucus hydration and clearance. Trikafta addresses the underlying cause of cystic fibrosis rather than only treating symptoms.
In people with CFLD, treating the underlying CFTR defect may also support liver health. Trikafta is not used on its own. It is part of routine CF care, with regular monitoring such as Liver Function Tests (LFTs).
LIVER BENEFITS
Cystic fibrosis is caused by a defective CFTR protein. Trikafta improves the processing and trafficking of this protein. In plain terms, the cell can build it and move it to where it needs to go more effectively. This step improves how the defective protein is processed and how it is moved within the cell.
Trikafta increases the amount of functional CFTR protein at the cell surface. This is central to correcting the underlying defect in CF, because the protein can only do its job when it reaches the cell surface. By raising the amount of working protein there, Trikafta targets the underlying cause of CF rather than only its symptoms.
When CFTR protein works better, chloride and water move more normally across epithelial cells. This enhances transport, improves mucus hydration, and improves mucus clearance, which supports lung function and overall health.
In people with cystic fibrosis-associated liver disease (CFLD), improving the underlying CFTR defect may also help support liver health. Trikafta is not specifically approved to treat liver disease, so your provider will keep monitoring your liver during treatment. Liver benefit is possible but not guaranteed, and liver function tests are checked regularly. Trikafta does not replace routine CF or liver care.
Trikafta treats the underlying CFTR defect in cystic fibrosis. It may also support liver health in CFLD, but it is not approved for liver disease. It should only be started and monitored by a qualified healthcare professional.
TREATMENT PROCESS
Trikafta comes as oral tablets: a morning combination tablet and an evening ivacaftor tablet.
Typical adult and eligible pediatric dosing is two combination tablets each morning and one ivacaftor tablet each evening, about 12 hours apart. Each morning tablet contains elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg. The evening tablet contains ivacaftor 150 mg. Your provider may adjust the dose if you have liver impairment or take certain other medications.
Take Trikafta with fat-containing food to improve absorption. Swallow the tablets whole. Use it exactly as your healthcare provider directs.
Trikafta is long-term, ongoing therapy, often lifelong, to maintain CFTR function and clinical stability. Do not stop taking it without first talking to your healthcare provider.
Store tablets at room temperature, away from moisture and heat.
Your healthcare provider will regularly check liver function tests and your overall response to treatment. Eye examinations are recommended for children. Report any side effects or unusual symptoms to your provider.
BENEFITS AND SAFETY
Trikafta corrects the function of the defective CFTR protein. This helps improve breathing and lung health, reduces pulmonary exacerbations (flare-ups), and improves daily functioning. It may also provide benefits across multiple organs affected by cystic fibrosis. The extent of these benefits varies from person to person.
As with any medication, Trikafta can cause side effects. One of the listed side effects is elevated liver enzymes, so your healthcare provider will monitor your liver function throughout treatment and assess whether Trikafta remains a suitable option for you.
BENEFITS
Trikafta improves the function of the defective CFTR protein. This addresses the underlying cause of cystic fibrosis rather than only treating symptoms, and it is the starting point for the other benefits listed here.
By improving chloride and water transport and helping clear mucus, Trikafta helps improve breathing and pulmonary health. This matters because lung problems are a major part of cystic fibrosis.
Trikafta reduces pulmonary exacerbations, or flare-ups of lung symptoms, and improves daily functioning. Fewer flare-ups can make everyday routines easier to keep up.
Cystic fibrosis affects more than one organ. Trikafta may provide benefits across multiple organs affected by CF, and in people with CFLD it may help support liver health. The extent of these benefits varies from person to person.
Your healthcare provider will discuss the potential benefits and risks before treatment and provide ongoing support, including liver function monitoring, to help ensure safe use.
SUPPORTING YOUR RESULTS
Trikafta works best alongside your routine CF care. Good nutrition, airway clearance, and avoiding smoke exposure all play a role.
These habits can support how your body responds to treatment over time.
Areas that may support treatment:
COMMON QUESTIONS
Trikafta is for people who have cystic fibrosis (CF) with an eligible CFTR gene mutation. Genetic testing confirms whether you are eligible for CFTR modulator therapy. Your provider may also consider it if you need treatment to improve CFTR protein function or have lung symptoms of CF. Your medical history, liver condition, and other medications also factor into the decision. Talk with your healthcare provider to find out whether Trikafta is right for you.
No. Trikafta (elexacaftor, tezacaftor, ivacaftor) is a prescription medicine for cystic fibrosis in people with eligible CFTR mutations, and it is not specifically approved to treat liver disease. In people with cystic fibrosis-associated liver disease (CFLD), improving the underlying CFTR defect may also help support liver health. That benefit is possible but not guaranteed. Ask your healthcare provider what to expect for your liver and whether you need other liver care.
Trikafta helps by improving how the defective CFTR protein works. It improves the processing and trafficking of the protein and increases the amount of working CFTR protein at the cell surface. This supports chloride and water movement across cells, which improves mucus hydration and clearance. Trikafta addresses the underlying cause of cystic fibrosis rather than only treating symptoms. Your healthcare provider can explain what to expect in your situation, since benefits vary from person to person.
You take Trikafta as oral tablets: a morning combination dose and an evening ivacaftor tablet, about 12 hours apart. Take it with fat-containing food to help your body absorb it, and swallow the tablets whole. Store tablets at room temperature, away from moisture and heat. Your provider may adjust the dose if you have liver impairment or take certain other medications, so follow your provider's instructions exactly.
Trikafta is usually long-term treatment, often lifelong. It is ongoing therapy that helps maintain CFTR function and clinical stability in people with cystic fibrosis. Do not stop taking it without first talking to your healthcare provider. Regular checkups, including liver function tests, help your care team see how well treatment is working and whether any changes are needed.
Common side effects include headache, upper respiratory tract infection, abdominal pain, diarrhea, and elevated liver enzymes. Your healthcare provider will discuss the potential benefits and risks before you start and will support you throughout treatment. Report any side effects or unusual symptoms to your provider. Do not change or stop your medicine on your own. Ask your provider first.
Your healthcare provider will regularly check liver function tests during Trikafta treatment. This matters because elevated liver enzymes are a listed side effect. Monitoring also helps your provider decide whether Trikafta remains a suitable option for you and whether your dose needs adjusting, for example if you have liver impairment. Children also need eye examinations. Ask your provider how often you will have blood tests.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
